Document 1081
 DOCN  M9471081
 TI    Hypercalcemia in intermediate grade non-Hodgkin's lymphoma (NHL)
       (Meeting abstract).
 DT    9409
 AU    Jendiroba DB; Seymour JF; Swan F; Cabanillas F; UT MD Anderson Cancer
       Center, Houston, TX 77030
 SO    Proc Annu Meet Am Soc Clin Oncol; 13:A1285 1994. Unique Identifier :
       AIDSLINE ICDB/94601281
 AB    The incidence, features and prognostic significance of hypercalcemia
       complicating NHL have not been determined. We analyzed 183 consecutive
       patients (pts) with untreated intermediate-grade NHL treated on protocol
       between 1988 and 1992. Hypercalcemia was defined as a corrected serum
       calcium (CCa) of greater than 10 mg/dl where CCa = total calcium +
       0.8[4.0 - albumin]. All pts were HIV seronegative and classified into
       favorable (n=44) or unfavorable (n=139) groups according to published
       criteria (Blood 74:551, 1989). Hypercalcemia (median CCa 10.4, range
       10.1-14.2) was more common among unfavorable pts (2% vs 19%, p=0.007).
       Limiting all further analyses to the unfavorable pts, there was no
       difference (p greater than 0.2) between those with high or normal CCa,
       respectively, in the incidence of T-cell phenotype (8% vs 6%) or bone
       lesions (both 12%). Adverse features were more common in pts with a high
       CCa: International Index greater than or equal to 3 (62% vs 35%,
       p=0.02), high LDH (88% vs 54%, p=0.005), beta2-microglobulin greater
       than or equal to 3 mg/l (64% vs 31%, p=0.002), PS greater than or equal
       to 2 (38% vs 15%, p=0.007). Despite identical therapy, pts with high CCa
       had shorter progression free (PFS) (p less than 0.01) and overall (OS)
       (p=0.01) survival. At 3 yr PFS was 57% vs 34% and OS 68% vs 38%,
       respectively. A high CCa at diagnosis was not always associated with a
       high CCa at relapse (18% vs 10%). Hypercalcemia in NHL is not isolated
       to pts with T-cell disease or bone lesions. A high CCa is a powerful
       adverse feature, possibly due to its association with other adverse
       indicators.
 DE    Calcium/BLOOD  Human  Hypercalcemia/*BLOOD/MORTALITY  Lymphoma,
       Intermediate-Grade/*BLOOD/MORTALITY  Paraneoplastic
       Syndromes/*BLOOD/MORTALITY  Prognosis  Survival Rate  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).